This approach is different from much of the existing literature because it moves beyond bone density alone and combines advanced imaging with fasting biochemical markers of bone turnover, body composition, dietary intake, physical activity, and sleep data collected longitudinally
Hepatic Inflammation-Fibrosis-Cancer axis in the Rat Hepatocellular Carcinoma Induced by Diethylnitrosamine
Additionally, Halden et al
For patients with type 2 diabetes and high cardiovascular risk, treatment with 0.5 mg Semaglutide has been linked to improvements in health-related quality of life including physical and emotional domains of health
#Inflammation #Nrf2 #NFkB #AdaptiveMedicine #SystemsBiology #Longevity #RootCauseMedicine To view or add a comment, sign in We are living through a massive paradigm shift in how medicine treats metabolic disease
Retatrutide is Eli Lilly's experimental triple-receptor agonist currently in Phase 3 clinical trials, activating GLP-1, GIP, and glucagon receptors